Priyanka Rajan’s indexed work centers on therapeutic strategies for p53-mutant and DNA-repair-dysregulated cancers, with a recent focus on modulating the immune microenvironment. Her most-cited publication, a 2024 *Cell Reports Medicine* study, describes a synergistic two-drug therapy that targets DNA repair dysregulation in p53-deficient colorectal and pancreatic cancers (16 citations). A 2023 *Nucleic Acids Research* paper compares cell response to chromatin versus DNA damage (11 citations), while a 2025 preprint outlines a sequential triple-drug strategy for selective targeting of p53-mutant cancers. Her first-author 2025 preprint on p38 blockade in metastatic breast cancer further explores immune-suppressive tumor microenvironment reversal. Beyond these core themes, Rajan contributed to a 2017 eBook chapter on berberine as an adjuvant and sensitizer to current chemotherapy